AMR Of Heart Transplants: Emerging Knowledge
Published: April 02, 2015
- Antibody-mediated rejection (AMR) is associated with transplant failure, reduced survival, increased rate of coronary allograft vasculopathy (CAV), and overall poor prognosis.
- Recent updates to the definition of AMR are expected to reduce variation in the diagnosis of AMR, allowing the development of more standardized therapies.
- This scientific statement provides an overview of the current diagnosis and treatment of AMR following cardiac transplant and includes recommendations for evolving standardization and future study.
- Commentary: Work in Progress: The Current State of Antibody Mediated Rejection by Scott R. Auerbach, MD and Shelley D. Miyamoto, MD
- Top Things to Know: Antibody-Mediated Rejection in Cardiac Transplantation
- Prognostic Value of Rubidium-82 Positron Emission Tomography in Patients After Heart Transplant (PDF)
- Cost-Effectiveness of Routine Surveillance Endomyocardial Biopsy After 12 Months Post–Heart Transplantation (PDF)
- Association of Human Leukocyte Antigen Donor–Recipient Matching and Pediatric Heart Transplant Graft Survival (PDF)
- Decision Making in Advanced Heart Failure: A Scientific Statement From the American Heart Association (PDF)
- ACCF/AHA/ACP/HFSA/ISHLT 2010 Clinical Competence Statement on Management of Patients With Advanced Heart Failure and Cardiac Transplant (PDF)